Synopsis A recent clinical study demonstrates that Cabozantinib increases survival rate in patients with advanced and progressive stages of Hepatocellular Carcinoma (HCC) This week's ' MED FACT' discusses a clinical trial from The New England Journal of Medicine, “C abozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma ”. 2018. Authors: Ghassan K. Abou-Alfa, Tim Meyer, Ann-Lii Cheng et al Key Takeaways Cabozantinib increases survival as well as progression-free survival (PFS) rates than placebo in patients with advanced and progressive stages of HCC who have received prior sorafenib.
Objective Study Type Participants To study the effect of Cabozantinib to placebo on overall survival rates in patients with advanced HCC who have received prior sorafenib. Randomized Controlled Trial (The CELESTIAL Trial) 704 What Was The Need For This Study? Cabozantinib…
